David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer 
    		2015 ASCO Annual Meeting
    	
    	
    	
    
        James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).
    
    
    
    
       
       
    		Laurie H. Sehn, MD, MPH
		
		
        
		
		
		
		Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
			
			
     	
    
       
       
    		Laurie H. Sehn, MD, MPH, and James O. Armitage, MD
		
		
        
		
		
		
		James O. Armitage, MD, of the University of Nebraska Medical Center, and Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discuss a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
			
			
     	
    
       
       
    		Jedd Wolchok, MD, PhD, and Anthony J. Olszanski, RPh, MD
		
		
        
		
		
		
		Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
			
			
     	
    
       
       
    		Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD
		
		
        
		
		
		
		Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).
			
			
     	
    
       
       
    		Anil D’Cruz, MD
		
		
        
		
		
		
		Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).